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Ű Supramolecular Nanoscience 
Shape-Persistent and Adaptive Multivalency ± Rigid Transgeden (TGD) 
and Flexible PAMAM Dendrimers for Heparin Binding 
Stephen M. Bromfield,ۆ[a] Paola Posocco,ۆ[b] Maurizio Fermeglia,[b] Juan Tolosa,[c] Ana 
Herreros-López,[c] Sabrina Pricl,*[b] Julián Rodríguez-López*[c] and David K. Smith*[a] 
Introduction 
Multivalency has emerged as one of the most important ways in 
which nanoscale recognition can be achieved in competitive 
media.1 Organising multiple ligands on the surface of a nanoscale 
architecture enhances binding as a consequence of entropic 
factors and an increase in local concentration of ligand at the 
binding interface.  Multivalent binding is of particular importance 
given that many biological objects, from cell membranes to 
proteins and nucleic acids, have nanoscale dimensions.  In recent 
times chemists have increasingly focussed on ways in which 
multivalent ligand arrays can be arranged to maximise binding. 
Dendrimers are well-defined molecules with repeating 
branched motifs, which therefore have multiple functional groups 
on their surfaces.2  As such, they constitiute one of the best ways 
of organising a multivalent ligand array.  Some of the simplest 
and best-known dendrimers exhibit multivalent binding to well-
known biological targets ± for example, poly(amidoamine) 
(PAMAM) dendrimers are used for DNA binding and gene 
delivery, with the polycationic surface amines of PAMAMs binding 
via multivalent electrostatic interactions and hydrogen bonding to 
the anionic phosphates on DNA.3  A number of reports have 
investigated the effect of dendritic size (generation) on binding ± 
for example it is known that for effective gene delivery, higher 
generation dendrimers are more effective as not only do they bind 
'1$LQDPRUHPXOWLYDOHQWPDQQHUEXWWKHµVSDUH¶ internal tertiary 
amines can buffer the interior of endosomes and assist 
endosomal escape ± a key step in gene delivery.4  PAMAM 
dendrimers have also been used to bind and deliver siRNA.5 
The ability of PAMAMs to achieve multivalent binding with 
other biomolecules has also been studied.  For example, heparin, 
an anionic polysaccharide, plays a key role as anti-coagulant 
during major surgery, and there has been considerable interest in 
developing heparin sensors6 and binders7 which have potential 
medicinal use either for quantifying heparin in the bloodstream or 
reversing the effect of heparin once surgery is complete.8 There 
have been several reports in which the interaction between 
PAMAM dendrimers and heparin has been quantified.9  In recent 
work, we established a new heparin binding dye-displacement 
assay to demonstrate that intermediate sized PAMAM dendrimers 
(G2 to G4) gave the most effective binding in terms of charge 
efficiency.10  Smaller G1 dendrimers were not sufficiently 
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Abstract: This paper investigates Transgeden (TGD) 
dendrimers (polyamidoamine (PAMAM) type dendrimers 
modified with rigid polyphenylenevinylene (PPV) cores) and 
compares their heparin-binding ability with commercially 
available PAMAM dendrimers.  Although the peripheral 
ligands are near-identical between the two dendrimer 
families, their heparin binding is very different. At low 
generation (G1), TGD outperforms PAMAM, but at higher 
generation (G2 and G3), the PAMAMs are better.  Heparin 
binding also depends strongly on the dendrimer:heparin 
ratio.  We explain these effects using multiscale modelling.   
TGD dendrimers exhibit µshape-persistent multivalency¶± the 
rigidity means that small clusters of surface amines are 
locally well optimised for target binding, but it prevents the 
overall nanoscale structure from rearranging to maximise its 
contacts with a single heparin chain.  Conversely, PAMAM 
dendrimers exhibit µDGDSWLYH multivalency¶ ± the flexibility 
means individual surface ligands are not so well optimised 
locally to bind heparin chains, but the nanostructure can 
adapt more easily and maximise its binding contacts.  As 
such, this paper exemplifies important new paradigms in 
multivalent biomolecular recognition. 
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multivalent to bind heparin effectively, while larger G6 dendrimers 
were unable to marshal all of their charges in heparin binding, 
and a significant number RIWKHPZHUHWKHUHIRUHµZDVWHG¶ 
There has been much interest in modified PAMAM structures 
for gene binding and delivery.  For example, more flexible 
PAMAM derivatives are highly effective.11  PAMAM dendrons 
have also been attached to flexible cores and used for DNA 
binding.12  Self-assembly of amphiphilic PAMAM dendrons into 
supramolecular dendrimers can enhance multivalent binding and 
biological activity.13  More rigid analogues of PAMAMs have also 
been reported ± for example the Transgeden dendrimers (TGDs, 
Figure 1).14  TGD dendrimers have conjugated photoactive 
poly(phenylene vinylene) (PPV) cores, with peripheral PAMAM-
like groups, and exhibit effective siRNA binding, delivery into 
neuronal cells, and also have useful optical properties. 
In this new paper, we wanted to explore the binding of TGDs 
to heparin.  We reasoned that using our recently developed 
Mallard Blue dye-displacement assay,10 we should be able to 
quantify the performance of TGD and compare the data to the 
original PAMAM dendrimers.  We hoped this would provide 
insight into the nature of the multivalent ligand display which can 
be achieved on different types of dendrimer scaffold ± flexible vs 
rigid. Other authors have explored dendrons for DNA binding and 
referred to them as flexible and/or rigid ± however, the structures 
were all relatively flexible and differences were limited. 15 
Figure 1.  Structures of PPV core and associated PAMAM surface groups for 
first (TGD-G1), second (TGD-G2) and third (TGD-G3) generation Transgeden 
hybrid dendrimers. 
Results and Discussion 
Experimental Study of Heparin Binding Using Mallard Blue 
Displacement Assay  
To study the binding of TGD dendrimers (Fig. 1) to heparin we 
employed our previously published Mallard Blue (MalB) indicator 
displacement assay conditions,10 in which a solution of dendrimer 
was titrated into a cuvette containing MalB and heparin before 
measuring the absorbance of the resulting solution. All 
concentrations, except that of the binder under test, were kept 
constant throughout the assay: MalB (25 µM), heparin (27 µM), 
NaCl (150 mM), Tris HCl (10 mM, pH 7.0).  Binding data are 
presented in terms of the effective concentration required to 
displace half of the MalB (EC50) from heparin, the charge excess 
of cationic binder at this point (CE50, i.e., the cation/anion ratio, 
assuming that dendrimer surface amines are all charged, and 
heparin has a tetra-anionic disaccharide repeat unit) and the 
effective dose of the binder (in mg per 100 international units [IU] 
of heparin) (Table 1).  As supplied, only ~30-40% of heparin 
chains have the active sequence of pentasaccharide repeat units 
which confer high anti-coagulant activity.  However, all of the 
material contains anionic saccharides, even if not active, which 
will be bound.  The heparin concentration in this paper refers to 
the total concentration of anionic disaccharide, irrespective of 
whether it is in the active form or not, and this value is used to 
calculate the CE50 and EC50 YDOXHV  )RU FDOFXODWLQJ WKH µGRVH¶, 
however, we reference the activity of the heparin binder only to 
the clinically active heparin (in IU).  It should also be noted that, 
as documented in the literature, this type of dendrimer is acutely 
sensitive to pH.16  In our assay (pH 7.0), only the primary amines 
at the dendrimer surface are protonated and only these charges 
are counted in calculation of CE50 values. 
 
Table 1. Heparin binding data for Transgeden (TGD) and Poly(amidoamine) 
(PAMAM) dendrimers 
Compound Surface 
Charge 
EC50 [PM][a] CE50[b] Dose[c] 
[mg/100IU] 
TGD-G1 +9 7.73 ± 0.32 0.64 ± 0.03 0.38 ± 0.02 
TGD-G2 +18 3.78 ± 0.25 0.63 ± 0.04 0.42 ± 0.03 
TGD-G3 +36 2.00 ± 0.15 0.67 ± 0.05 0.47 ± 0.04 
PAMAM-G1 +8 10.10 ± 0.32  0.75 ± 0.02 0.44 ± 0.01 
PAMAM-G2 +16 2.55 ± 0.32 0.38 ± 0.04 0.25 ± 0.03 
PAMAM-G3 +32 1.53 ± 0.21 0.45 ± 0.06 0.32 ± 0.04 
[a] EC50 is effective concentration of dendrimer for 50% displacement for 
MalB (25 PM) from heparin (27 PM tetra-anionic disaccharide). [b] CE50 is 
the charge excess (cation:anion) required for 50% displacement of MalB. [c] 
Dose is the mass of dendrimer required to bind 100IU of heparin. 
 
From the data in Table 1, it can be seen that all generations 
can bind heparin and displace MalB.  The higher generation 
TGDs operate at lower concentrations (i.e. EC50 decreases) ± this 
reflects the larger number of amines on their surfaces (see below).  
Interestingly, however, in charge efficiency terms, all three 
generations of TGD have very similar CE50 values for binding 
heparin.  Comparing the CE50 values of the TGD dendrimers 
therefore suggests that the larger dendrimers do not become 
more efficient on a per charge basis.  In terms of dose (by weight), 
the smallest dendrimer, with the lowest molecular mass, is 
actually the best heparin binder. 
These data are somewhat surprising, particularly if directly 
compared to the previously studied PAMAM dendrimers (Table 1).  
At low generation, TGD-G1 is more effective than PAMAM-G1 in 
terms of heparin binding.  In previous work, it was also found that 
TGD-G1 was the optimal system for gene delivery, combining 
good efficacy with low toxicity.14  However, at larger second and 
third generations, PAMAM dendrimers significantly improve their 
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performance while the TGD dendrimers do not.  As such 
PAMAM-G2 is the most effective heparin binder in terms of CE50 
by some margin over any of the TGD analogues.  The inferior 
performance of TGD with respect to native PAMAMs clearly 
suggests that the presence of the PPV core somehow alters the 
effectiveness of each charge at the dendrimer surface when 
binding heparin. We proposed that the rigid core may somewhat 
restrict the ability of the charges to cooperate as effectively as in 
unmodified PAMAMs, possibly by preventing the reorganisation 
of surface ligands (see modelling below for detailed discussion) ± 
we have previously reflected on the benefits of flexibility in 
multivalent arrays applied in DNA binding.17 
Importantly, however, it should be noted that consideration of 
only the CE50 values as described above significantly limits the 
information which can be extracted from the assay as it only 
focusses on the dendrimer performance when half of the MalB is 
displaced from its complex with heparin ± this corresponds to just 
one specific molar ratio of dendrimer:heparin.  The performance 
of dendrimers may of course vary with molar ratio, depending on 
the stoichiometries of the complexes which can be formed.  As 
such, it is worth looking at data from across the whole range of 
concentrations in a comparative sense. 
Figure 2.  Titration of TGD and PAMAM dendrimers to displace MalB from its 
complex with heparin. Top, TGD-G1 and PAMAM-G1; Centre, TGD-G2 and 
PAMAM-G2; Bottom, TGD-G3 and PAMAM-G3. 
Comparing low generation TGD-G1 and PAMAM-G1 (Fig. 2), 
it is clear that TGD outperforms PAMAM across the whole assay.  
As such, the CE50 value is a fair reflection of the overall data.  
Conversely, when comparing TGD-G2 and PAMAM-G2, or TGD-
G3 and PAMAM-G3 (Fig. 2), when small amounts of TGD are 
present, TGD performs slightly better than PAMAM.  However, as 
more dendrimer is added, the performance of TGD drops off, at 
which point PAMAM performs much better, and hence the CE50 
values for PAMAM-G2 and PAMAM-G3, which sample just a 
single point of each experiment, appear much better than those 
for TGD-G2 and TGD-G3.   
We propose that at low levels of dendrimer, the surface of the 
dendrimer will be saturated with binding interactions to multiple 
heparin chains ± and we suggest that for TGD these interactions 
are quite well organised and strong.  However, as the amount of 
TGD increases, there is less available heparin and each 
dendrimer will increasingly be forced to form interactions with just 
a single heparin chain ± we suggest that TGD is less able to do 
this than PAMAM, perhaps as a consequence of TGD having 
higher rigidity and an inability to rearrange its surface to achieve 
effective binding of all surface groups (see modelling below). 
Importantly, these data clearly show that charge alone is not 
enough to act as a simple predictor of heparin binding ± if it did, 
then PAMAM and TGD dendrimers should have very similar 
heparin binding performance.  It is sometimes suggested that 
when using electrostatic ion-ion interactions to bind polyanions, 
only the total charge and/or charge density are important.18  It is 
also sometimes stated that selectivity can be very hard to achieve 
in ion-ion binding for this reason.  However, our data show that 
quite simple changes can have a dramatic impact on the use of 
charge in binding.  As such we suggest that spatial organisation 
is vital in this binding event and that careful charge organisation is 
a viable strategy through which selective ion-ion interactions in 
highly competitive aqueous media can be achieved. 
To understand these experimental binding data, we decided 
to employ multiscale modelling in order to better answer the 
following questions: 
(i) Why does TGD-G1 perform better than PAMAM-G1? 
(ii) Why do PAMAM-G2 and G3 perform better than TGD-G2 and 
G3 at the CE50 value when more dendrimer is present? 
(iii) Why do TGD-G2 and TGD-G3 appear to bind effectively to 
heparin when present in small amounts? 
(iv) Why is the charge ratio-dependent behaviour different to that 
observed for PAMAM? 
We reasoned that answering these questions would yield a 
detailed insight into multivalency effects and might help us 
understand the impact of rigid/flexible interiors on the behaviour 
of dendritic surface groups. 
 
Theoretical Study of Heparin Binding Using Multiscale 
Modelling Methods19 
 
i) Atomistic Molecular Dynamics Modeling at Charge Excess 
(CE) of 0.4 
We started our modelling study by considering the performance 
of the dendrimers close to the CE50 value, at a consistent charge 
excess of 0.4 (cation:anion) using an atomistic molecular 
dynamics (MD)20 approach.  We used on a heparin chain with 
tetra-anionic disaccharide repeat units and the number of binding 
dendrimers was adjusted appropriately to give the required 
charge ratio of 0.4.    
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Table 2. Binding parameters from MD simulations at a charge excess of 0.4. 
Compound Nmol[a] Qtot[b] Qeff[c] 'Gbindeff (kcal/mol)[d] 'Gbindeff/Qtot (kcal/mol)[e] 'Gbindeff/Qeff (kcal/mol)[f] 
TGD-G1 4 36 26 ± 2 -9.6 ± 0.8 -0.27 ± 0.02 -0.37 ± 0.03 
TGD-G2 2 36 21 ± 1 -9.9 ± 0.6 -0.28 ± 0.02 -0.47 ± 0.03 
TGD-G3 1 36 14 ± 1 -10.1 ± 0.7 -0.28 ± 0.02 -0.72 ± 0.05 
PAMAM-G1 5 40 35 ± 2 -10.2 ± 1.1 -0.26 ± 0.03 -0.29 ± 0.03 
PAMAM-G2 2 32 29 ± 1 -44.7 ± 2.0 -1.40 ± 0.06 -1.54 ± 0.07 
PAMAM-G3 1 32 15 ± 1 -15.9 ± 1.1 -0.50 ± 0.03 -1.06 ± 0.07 
[a] Nmol is the number of dendrimer molecules included in the model. [b] Qtot is the total positive charge associated with the 
dendrimers. [c] Qeff is the number of positively charged amines on the dendrimers making effective binding contacts with heparin. [d] 
'Gbindeff is the total effective free energy of binding between the dendrimers and heparin. [e] 'Gbindeff/Qtot relates to the experimental 
CE50 value and indicates how well the total charge of the dendrimer is used in binding heparin. [f] 'Gbindeff/Qeff represents how 
effective each active contact is in binding to heparin. 
 
 
 
 
Figure 3.  TGD-G1-G3 (left panels, top to bottom) and PAMAM-G1-G3 (right panels, top to bottom) dendrimers bound to heparin at a charge excess of 0.4 using MD 
modelling methods.  TGD and PAMAM molecules are portrayed as pink and green sticks-and-balls, respectively.  Heparin is shown as a chain of L-iduronic acid 
(blue) and D-glucosamine (light blue) alternating units.  Some Na+ and Cl- counterions are shown as small and large pink and grey shaded spheres respectively.  
Water is not shown for clarity. 
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In the experimental data, at a charge excess of 0.4, 
PAMAM-G2 and PAMAM-G3 significantly outperform the TGD 
analogues, while TGD-G1 performs slightly better than PAMAM-
G1.  At this charge ratio there is approximately one TGD-G3 or 
PAMAM-G3 molecule per heparin chain (as modelled), two TGD-
G2 or PAMAM-G2 molecules and ca. four (or five) TGD-G1 (or 
PAMAM-G1) molecules.  The total charge associated with all of 
the dendrimers in the simulation is Qtot.  Using MD methods, we 
then calculate the total effective binding energy 'Gbindeff of these 
dendrimers with heparin.   We can then normalise this by dividing 
by the total dendrimer charge present in the simulation (Qtot).  
This should relate to the experimentally observed charge excess 
values, which are also calculated based on the total charge of 
dendrimer surface groups.  We can also calculate the number of 
effective surface charges (that is, the charged residues actively 
contributing to binding to the heparin chain, Qeff) and work out the 
effective binding energy of each active/binding surface charge 
with heparin ('Gbindeff/Qeff). 
Considering the data (Table 2) confirms that under these 
conditions, PAMAM-G2 and PAMAM-G3 are indeed the most 
effective heparin binders ± in good agreement with the 
experimental observations.  Furthermore, in terms of how the 
total charge of the dendrimer is used, TGD-G1, TGD-G2 and 
TGD-G3 all appear to be identical ('Gbindeff/Qtot = ca. -0.28 
kcalmol-1) ± reflecting the CE50 values measured experimentally.  
Notably, TGD-G1 is also better than, or comparable with, 
PAMAM-* RQ D µSHU GHQGULPHU¶, RU µSHU FKDUJH¶, basis ± once 
again in agreement with the experimental observations. 
To understand differences in binding more precisely, and 
explore multivalency effects, it can be instructive to consider the 
performance of each active individual charge directly involved in a 
binding interaction.  Considering the TGD dendrimers, it is clear 
that as the dendrimer becomes larger, fewer of the surface 
charges can actually contact heparin.  This reflects the rigidity of 
the dendrimers, making it impossible for the surface charges to 
rearrange enough to bind to the heparin.  For TGD-G1, 72% of 
the surface charges actively bind to heparin; this drops to 58% for 
TGD-G2 and 39% for TGD-G3.  For the larger TGD dendrimers, 
those surface charges which do bind however, do so more 
effectively (as reflected in the effective binding energy of each 
active/binding surface charge, 'Gbindeff/Qeff) ± but this only just 
manages to counterbalance the decrease in the number of such 
interactions ± so the overall charge efficiency across all charges 
('Gbindeff/Qtot) remains constant.  Figure 3 shows a snapshot of 
the modelling of heparin binding, indicating how a significant 
number of the surface charges for TGD-G2 and TGD-G3 simply 
cannot make contact with heparin.  It appears that localised 
clusters of amines on the TGD surfaces appear to make contact ± 
and we suggest that these are well-organised locally to bind 
heparin. 
For the PAMAM dendrimers, the behaviour is significantly 
different ± this is largely a consequence of the greater flexibility of 
the PAMAM structures.  For PAMAM-G1, 87.5% of the available 
surface charges make good contact with heparin, and for 
PAMAM-G2 and PAMAM-G3 this value is 91% and 47%, 
respectively.  These values are much larger than for TGD and 
reflect the flexible interior of PAMAM allowing significant 
reorganisation of the surface groups so that many more of them 
can interact with heparin.  This can clearly be visualised in Figure 
3 in which the PAMAM dendrimers rearrange and wrap their 
surface charges around the heparin polymer chain as best they 
can.  We define this proFHVVDV µDGDSWLYHPXOWLYDOHQF\¶± similar 
ability of flexible binding arrays to adapt at a binding interface 
have been previously noted.17,21 
Comparing PAMAM-G1 with TGD-G1, it is clear that although 
the greater rigidity of TGD-G1 limits the number of surface 
charges which make contact with a single heparin chain, each 
individual active contact is more effective than for PAMAM-G1 (-
0.37 kcal/mol vs -0.29 kcal/mol).  This suggests that the cationic 
surface groups of rigid TGD-G1 are better pre-organised to bind 
heparin ± but that once some of them have bound to the heparin 
chain, the molecule does not possess enough flexibility for the 
others to also come into contact with it (Fig. 3).  It can be 
considered on structural grounds (Fig. 1) that TGD-G1 contains 
three separate groups of surface amines, each containing three 
locally pre-organised positive charges.  Conversely, PAMAM-G1 
does not locally organise small groups of amine, but its flexibility 
means that it can bring more of its weaker interactions to bear on 
the overall binding event across the whole dendrimer. 
 
ii) Mesoscale Dissipative Particle Dynamics Modeling at CE 
0.1 
We then wanted to probe in more detail what happens at lower 
charge excess in the binding experiment (i.e. when a greater 
excess of heparin is present relative to dendrimer).  Under these 
conditions, all of the TGD dendrimers appear experimentally, to 
perform somewhat better relative to PAMAM.  We therefore 
performed mesoscale simulations using Dissipative Particle 
Dynamics (DPD)22 at a charge excess of 0.1 (cation:anion) ± this 
situation was ideal for mesoscale modelling as a consequence of 
the presence of multiple heparin chains and complex 
stoichiometries.  Under these conditions, there is significantly 
more heparin relative to the dendrimers than in the MD modelling 
described above, and multiple heparin chains are now able to 
make contact with a single dendrimer.  Obviously, in this case, 
the flexibility of the dendrimer, and the ability of multiple surface 
groups to make contact with a single heparin chain through 
adaptive multivalency, as described above, should become less 
relevant. 
Figure 4 illustrates the binding of TGD-G1-G3 (top) and 
PAMAM-G1-G3 (bottom) to heparin.  For the G1 systems, the 
heparin-dendrimer interactions are well-defined, with the 
geometry and conformation of TGD-G1 playing a key role in the 
binding process ± more so than for PAMAM-G1 ± we suggest this 
is a result of the greater rigidity of TGD providing local 
organisation of the surface ligands.  As the generation of TGD 
increases, binding becomes less well-defined, with multiple 
heparins contacting one dendrimer.  The stoichiometry of DNA 
binding has previously been considered in a similar way for PEI 
dendrimers.23  The stoichiometry can be qualitatively appreciated 
by comparing the left and right panels of Figure 4; in the case of 
G1, mostly 1:1 dendrimer/heparin assemblies prevail (left-most 
panel) while for G3, several heparin chains contact a single 
dendrimer.  This stoichiometry allows the formation of significantly 
more high affinity interactions for TGD than are present at higher 
charge excesses when less heparin is available.  TGD suffered at 
a higher charge excess from not being able to use all of the rigidly 
displayed surface charges ± conversely at lower charge excess 
they can now contact different parts of their well-optimised 
structure to different heparin chains significantly assisting binding.   
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Figure 4.  Zoomed view of the mesoscopic simulation of TGD and PAMAM  dendrimers in complex with heparin at a charge excess of 0.1. Top (left to right) = TGD-
G1, TGD-G2 and TGD-G3 binding to heparin.  Bottom (left to right) = PAMAM-G1, PAMAM-G2 and PAMAM-G3 binding to heparin. PAMAM  and TGD dendrimers 
are portrayed as green and pink spheres, respectively. Charged amine groups are depicted in light green for both families. Heparin is shown as a chain of L-iduronic 
acid (blue) and D-glucosamine (light blue) alternating units. A transparent grey field is used to represent water and ions. 
:HGHILQHWKLVDVµVKDSH-SHUVLVWHQWPXOWLYDOHQF\¶DQGSURSRVH
that this explains why TGD dendrimers appear to perform more 
effectively at low charge excess, but less effectively at high 
charge excess. 
To summarise the modelling studies, and answer the 
questions opened up by the experimental investigation: 
(i) The rigidity of TGD-G1 means the surface ligands are 
displayed in a more locally organised, shape-persistent manner 
for heparin binding than on PAMAM-G1   
(ii) The greater flexibility of PAMAM-G2 and PAMAM-G3 allows 
them to display adaptive multivalency and bring more of their 
surface groups into contact with a single heparin chain than TGD-
G2 or TGD-G3 
(iii) At low charge excess, multiple heparins can make contact 
with different parts of the locally organised surface of TGD-G2 
and TGD-G3, which means that their shape-persistent multivalent 
surface ligands can all contribute to binding ± leading to an 
improvement in relative performance under these conditions 
(iv) The flexibility of the PAMAM dendrimers means they are 
better able to adapt to different binding stoichiometries and 
perform reasonably well at both low and high charge excesses. 
 
Investigation of Heparin Binding Using Modified TGDs 
To gain further insight into the role of surface charge in heparin 
binding, we investigated a family of modified TGD-G1 dendrimers 
in which some (or all) of the surface amines have been replaced 
with alcohol groups (Fig. 5).24  This was done in a statistical 
manner during synthesis, and the degree of amine 
functionalisation estimated using a Kaiser test.  Table 3 lists 
these dendrimers along with their estimated surface charge (in 
brackets) and details of their heparin binding performance. These 
data clearly show that none of the modified TGD-G1 dendrimers 
bind heparin as efficiently as TGD-G1. It is perhaps most 
interesting that removal of less than 20% of the positive charges 
from the periphery of TGD-G1 to afford TGD-G1 (+7.4) reduces 
the efficiency of each charge in binding by more than half.  
Figure 5.  Structures of TGD-G1 with different levels of amine replacement by 
alcohol groups, including complete replacement (TGD-G1(OH)9) 
Table 3. Heparin binding data for Modified Transgeden (TGD) 
dendrimers 
Compound EC50 [PM][a] CE50[b] Dose[c] 
[mg/100IU] 
TGD-G1 7.73 ± 0.32 0.64 ± 0.03 0.38 ± 0.02 
TGD-G1 (+7.4) 19.2 ± 2.7 1.31 ± 0.18 0.94 ± 0.13 
TGD-G1 (+6.2) weak binding weak binding weak binding 
TGD-G1 (+4.0) weak binding weak binding weak binding 
TGD-G1(OH)9 no binding no binding no binding 
 
This suggests that all of the charged amines on the surface 
of the dendrimer are important, and that the absence of even a 
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few is significant.  When even more amines are removed, the binding becomes very weak. 
Table 4. Binding parameters from MD simulations at a charge excess of 0.4. 
Compound Nmol[a] Qtot[b] Qeff[c] 'Gbindeff (kcal/mol)[d] 'Gbindeff/Qtot (kcal/mol)[e] 'Gbindeff/Qeff (kcal/mol)[f] 
TGD-G1 4 36 26 ± 2 -9.6 ± 0.8 -0.27 ± 0.02 -0.37 ± 0.03 
TGD-G1 (+7.4) 5 37 23 ± 1 -7.0 ± 0.4 -0.19 ± 0.01 -0.30 ± 0.02 
TGD-G1 (+6.2) 6 37.2 23 ± 1 -4.9 ± 0.6 -0.13 ± 0.01 -0.21 ± 0.03 
[a] Nmol is the number of dendrimer molecules included in the model. [b] Qtot is the total positive charge associated with the 
dendrimers. [c] Qeff is the number of positively charged amines on the dendrimers making effective binding contacts with heparin. [d] 
'Gbindeff is the total effective free energy of binding between the dendrimers and heparin. [e] 'Gbindeff/Qtot relates to the experimental 
CE50 value and indicates how well the total charge of the dendrimer is used in binding heparin. [f] 'Gbindeff/Qeff represents how 
effective each active contact is in binding to heparin.   
 
MD simulations of modified TGDs in the presence of heparin 
were performed at a charge excess of 0.4.  As can be seen 
(Table 4), the binding decreases significantly on a per charge 
basis ('Gbindeff/Qtot) ± in agreement with the decrease observed 
experimentally in EC50 values.  These data agree with a model in 
which the smaller parts of the rigid TGD dendrimer surface act 
fairly independently in terms of binding to heparin, with their 
rigidity limiting their ability to make the whole dendrimer surface 
cooperate.  Given that TGD-G1 can be considered as containing 
three locally organised surface regions, each with three amines, 
we suggest statistically replacing just one of these three amines, 
has a significant negative impact on the binding of each surface 
group to heparin and hence considerably weakens binding. 
Plotting the data in terms of charge excess (Fig. 6) provides 
an excellent example of multivalent charge organisation. By 
definition in this graph, there is the same total amount of positive 
charge present at each charge ratio, yet it is absolutely clear that 
TGD-G1 strongly outperforms the other dendrimers and has the 
best interactions with heparin as a consequence of its better 
locally organised multivalent binding surface. 
 
Figure 6. Binding curve comparison between TGD-G1, TGD-G1 (+7.4), TGD-
G1 (+6.2), TGD-G1 (+4.0) and TGD-G1(OH)9 expressed as a function of charge 
ratio.   
Experimental Study of Heparin Binding Using the Inherent 
Fluorescence of TGD Dendrimers 
Unlike PAMAM dendrimers, one key advantage of TGD 
dendrimers is that they have an inherent photophysically-active  
 
unit within their structure.  As such, we can study heparin binding 
directly; in the absence of an indicator dye. 
 
Figure 7. Plot of change in fluorescence intensity of a solution of dendrimer (1 
µM) at 427 nm following irradiation at 318 nm against concentration of heparin: 
A, TGD-G1; B, TGD-G2; C, TGD-G3. 
TGD-G1 has an absorbance maximum at 319 nm in water 
which, following irradiation, exhibits a complementary 
fluorescence output at 399 nm and 413 nm.25 As such, a series of 
experiments was designed to titrate a solution of Transgeden 
(TGD-G1, TGD-G2 or TGD-G3) with heparin and monitor the 
spectroscopic response.  Transgeden (1 PM) solutions were 
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made in aqueous solution in the presence of Tris-HCl buffer (10 
mM, pH 7.0) and NaCl (150 mM).  Plotting the resulting 
fluorescence intensity at Omax (427 nm) against concentration of 
heparin yields the graphs in Figure 7. 
For the larger dendrimers TGD-G2 and TGD-G3, 
conventional binding curves are observed, with an increase in 
fluorescence intensity on binding and saturation of fluorescence 
intensity.  The higher generation dendrimer saturates at a larger 
heparin concentration, reflective of the greater number of heparin 
binding surface sites.  The stoichiometry of the binding profiles 
would suggest saturation binding of two heparin disaccharide 
units (2 PM) to TGD-G2 and six (6 PM) to TGD-G3.  This is in 
excellent agreement with the MD modelling illustrated in Figure 3 
which indicates that this many disaccharide units can be covered 
by each dendrimer.  The increase in fluorescence intensity may 
suggest that on binding, the core becomes more rigid, limiting 
non-radiative decay processes.26  Conversely, TGD-G1 shows 
quite different behaviour, with some quenching of the 
fluorescence associated with the PPV core being initially 
observed before an increase in intensity.  We suggest there may 
be some more direct interaction between bound heparin and 
fluorophore in this case meaning different effects are associated 
with different stoichiometries of complex (quenching versus 
rigidification), leading to the uninformative titration curve. 
Nonetheless, it is clear that dendrimers TGD-G2 and TGD-G3 
self-indicate heparin binding as a consequence of their optical 
properties, and act as heparin sensors.  Clearly this role cannot 
be fulfilled by PAMAM dendrimers.  There is a need for heparin 
sensors which can be used to detect heparin in plasma and given 
the large fluorescent response of TGD-G2 in competitive 
conditions of buffer and electrolyte, we suggest that this could be 
DFDQGLGDWHKHSDULQVHQVRU µ6ZLWFKRQ¶IOXRUHVFHQFHVHQVLQJRI
this type is potentially useful in a clinical setting.8 
Conclusion 
In summary, we have demonstrated that TGD dendrimers appear, 
in general, to be less effective heparin binders than their PAMAM 
analogues.  At low generation, TGD-G1 is better, but at higher 
generation, the PAMAM systems are better.  However, the ability 
to bind also depends strongly on the ratio of dendrimer:heparin.  
In particular, in the presence of excess heparin, a clinically 
relevant situation, TGDs outperform PAMAMs.  We can explain 
this in terms of the structure and dynamics of the dendrimer 
nanostructures as probed using multiscale modelling methods.  
We consider the TGD dendrimers to display shape-persistent 
multivalency, in which the rigidity means that small 
clusters/patches of surface amines are locally well-organised for 
target binding, but the overall nanoscale structure is not 
sufficiently flexible to maximise all of its contacts with a single 
heparin binding partner.  PAMAM dendrimers conversely, 
exemplify adaptive multivalency, in which individual surface 
ligands are not so well locally optimised for target binding, but the 
flexibility of the overall nanostructure allows it to adapt its global 
shape more easily and hence maximise the total number and 
efficiency of contacts with the binding partner. Usefully, the rigid 
conjugated core of TGD dendrimers endows them with optical 
properties, and TGD-G2 and TGD-G3 can operate DVµVZLWFK-RQ¶
fluorescence sensors for heparin binding in competitive media. 
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